부산대학교 도서관

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Varicella Vaccine and Measles, Mumps and Rubella Combined Vaccine in Shanghai, China: A Non-inferiority, Open-label, Randomised, Controlled, Phase 4 Trial

Immunogenicity and Safety of Adsorbed Diphtheria, Tetanus, Acellular Pertussis Combined Vaccine or Adsorbed Diphtheria Tetanus Combined Vaccine in 6 Years Old Children#a Randomized, Controlled Clinical Study

Immunogenicity and Safety of Adsorbed Diphtheria, Tetanus, Acellular Pertussis Combined Vaccine or Adsorbed Diphtheria Tetanus Combined Vaccine in 6 Years Old Children：a Randomized, Controlled Clinical Study

China National Biotec Group Company Limited; Lanzhou Institute of Biological Products Co., Ltd

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

China National Biotec Group Company Limited; Lanzhou Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co Ltd.

A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above

China National Biotec Group Company Limited; Lanzhou Institute of Biological Products Co., Ltd; Beijing Insitute of Biological Products Co., Ltd

A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun. 2022 Jun 27;13(1):3654. doi: 10.1038/s41467-022-31379-0.

China National Biotec Group Company Limited; Lanzhou Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co Ltd.

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of LIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) in Healthy Population Aged 18 and Above

Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV)

Beijing Institute of Biological Products Co Ltd.; China National Biotec Group Company Limited; Fundación Huésped

Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years

China National Biotec Group Company Limited; Beijing Tiantan Biological Products Co., Ltd.

A Randomized, Double-blind, Placebo-controlled Phase II Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Human COVID-19 Immunoglobulin (pH4) for Intravenous Injection (COVID-HIG) in the Treatment of Patients With COVID-19

Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants
He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, Xie S, Wen N, An Z, Chen Z, Wang H. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis. 2020 Sep;20(9):1071-1079. doi: 10.1016/S1473-3099(19)30738-8. Epub 2020 May 19.

Nawal Al Kaabi; Yunkai Yang; Salah Eldin Hussein; Tian Yang; Jehad Abdalla; Hui Wang; Zhiyong Lou; Chinese Center for Disease Control and Prevention; Agyad Bakkour; Afnan Arafat; China National Biotec Group Company Limited; Zhiwei Jiang; Ye Tian; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd.; Beijing Institute of Biological Products Company Limited; Peng Xiao; Walid Zaher; Islam Eltantawy; Chenlong Wang; Guangxue Xu; Yuntao Zhang; Xiaoming Yang

Vaccines, Vol 11, Iss 2, p 299 (2023)

Phase 4 Study of Post-License Safety Evaluation of Influenza Split Vaccine

The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine

Liu X; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.; Han S; Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.; Chen X; Immunization Program Division, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.; Sun L; Department of Immunization Program Administration, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.; Wang R; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.; Shi X; Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.; Guo Y; Department of Immunization Program Administration, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.; Wang H; Immunization Program Division, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.; Chen H; Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.; Chang S; Immunization Program Division, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.; Xu X; Department of Immunization Program Administration, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.; Zhang C; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.; Wang Y; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.; Zhang D; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.; Hu W; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.; Zhang S; Monitoring and Early Warning Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi, China.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Liu X; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, China.; Han S; Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.; Wang H; Immunization Program Division, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.; Sun L; Department of Immunization Program Administration, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.; Zhang C; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, China.; Chen X; Immunization Program Division, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.; Wang R; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, China.; Chang S; Immunization Program Division, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.; Shi X; Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.; Chen H; Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.; Wang Y; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, China.; Zhang D; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, China.; Guo Y; Department of Immunization Program Administration, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.; Zhang S; Monitoring and Early Warning Division, Shaanxi Provincial Administration for Disease Control and Prevention, Xi'an, China.; Hu W; Immunization Program Division, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, China. Electronic address: huweijun0828@163.com.

Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE

Tang X; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.; Xiao Y; China National Biotec Group Company Limited, Beijing, China.; Chen J; Yiwu Center for Disease Control and Prevention, Jinhua, China.; Su Y; Zhejiang Chinese Medical University, Hangzhou, China.; Zhou Y; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.; Luo L; China National Biotec Group Company Limited, Beijing, China.; Zhang J; Wuhan Institute of Biological Products Company Limited, Wuhan, China.; Liu S; Chengdu Institute of Biological Products Company Limited, Chengdu, China.; Yan R; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.; Zhu D; Wuhan Institute of Biological Products Company Limited, Wuhan, China.; Zhao W; Chengdu Institute of Biological Products Company Limited, Chengdu, China.; Zhu Y; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.; Ma X; National Institutes of Food and Drug Control, Beijing, China.; Jiang Y; Harvest integrated Research Organization (HiRO), Shanghai, China.; Pan H; China National Biotec Group Company Limited, Beijing, China.; Zhang Y; China National Biotec Group Company Limited, Beijing, China.; He H; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. hanqinghe@cdc.zj.cn.; Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Hangzhou, China. hanqinghe@cdc.zj.cn.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Liu H; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Vaccines R&D Department, Changchun Institute of Biological Products Co., Ltd., Changchun, Jilin, China.; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China.; Liu N; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Sun Y; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Li S; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Li H; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Wang M; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Shuang H; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; Cai Y; Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Shi Y; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.; Bi M; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233030, China.; Li Q; Department of Oncology, Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, China.; Wang G; Department of Thoracic Oncology, Henan Chest Hospital, Zhengzhou, Henan 450003, China.; Chen J; Department of Thoracic Medical Oncology, Hunan Cancer Hospital, Changsha, Hunan 410013, China.; Li M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.; Shi J; Department of Internal Medicine, Linyi Cancer Hospital, Linyi, Shandong 276002, China.; Mei J; Department of Medical Oncology, Zhengzhou People's Hospital, Zhengzhou, Henan 450003, China.; Ji Y; Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453199, China.; Xia Q; Department of Respiratory Medicine, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.; Feng Y; Department of Oncology, Xiangtan Central Hospital, Xiangtan, Hunan 411199, China.; Xu S; Department of Respiratory Diseases, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei 066099, China.; Zhang T; Department of Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Tumor Research Institute, Beijing 101125, China.; Gao X; Department of Medical Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471000, China.; Tang S; Department of Oncology, The First People's Hospital of Neijiang, Neijiang, Sichuan 641099, China.; Weng J; Department of Oncology, The First People's Hospital of Yueyang, Yueyang, Hunan 414020, China.; Cao Z; Department of Respiratory Medicine, Lishui People's Hospital, Lishui, Zhejiang 323000, China.; Wu H; Department of Respiratory Diseases, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.; Ren X; Department of Biotherapy and Key Laboratory of Cancer Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.; Xie H; Department of Oncology, People's Hospital of Xuancheng, Xuancheng, Anhui 242099, China.; Liu H; Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, Gansu 730099, China.; Liu Q; Department of Oncology, Shenyang Tenth People's Hospital, Shenyang, Liaoning 110044, China.; Yin X; Department of Oncology, Handan First Hospital, Handan, Hebei 056002, China.; Luo X; Department of Radiotherapy, The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, Henan 471099, China.; Chen J; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China.; Zhang H; Department of Medical Oncology, Central Hospital of Xiangtan, Xiangtan, Hunan 411104, China.; Guo Z; Department of Medical Oncology, Handan Central Hospital, Handan, Hebei 057150, China.; Ding C; Department of Respiratory Medicine, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei 050011, China.; Jin X; Department of Medical Oncology, Loudi Central Hospital, Loudi, Hunan 417099, China.; Sun R; Department of Respiratory Medicine, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong 266042, China.; Yang S; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.

Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 9918680788606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2949-7132 (Electronic) Linking ISSN: 29497132 NLM ISO Abbreviation: Cancer Pathog Ther Subsets: PubMed not MEDLINE

Tang X; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Xiao Y; China National Biotec Group Company Limited, Beijing, China.; Deng X; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Zhou Y; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Chen H; China National Biotec Group Company Limited, Beijing, China.; Yan R; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Zhu Y; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Wang S; China National Biotec Group Company Limited, Beijing, China.; Wang H; Beijing Institute of Biological Products Company Limited, Beijing, China.; Zhu X; Beijing Institute of Biological Products Company Limited, Beijing, China.; Luo L; China National Biotec Group Company Limited, Beijing, China.; Liu Y; Hangzhou Municipal Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Yin Z; Quzhou Municipal Center for Disease Control and Prevention, Quzhou, Zhejiang, China.; Zhang G; Chun'an County Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Chen Z; Longyou County Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Jiang J; Chun'an County Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.; Yang X; China National Biotec Group Company Limited, Beijing, China.; He H; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.

Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101774968 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-6065 (Electronic) Linking ISSN: 26666065 NLM ISO Abbreviation: Lancet Reg Health West Pac Subsets: PubMed not MEDLINE